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Activated caspases are a hallmark of apoptosis
induced by the intrinsic pathway, but they are
dispensable for cell death and the apoptotic clear-
ance of cells in vivo. This has led to the suggestion
that caspases are activated not just to kill but to
prevent dying cells from triggering a host immune
response. Here, we show that the caspase cascade
suppresses type I interferon (IFN) production by cells
undergoing Bak/Bax-mediated apoptosis. Bak and
Bax trigger the release of mitochondrial DNA. This
is recognized by the cGAS/STING-dependent DNA
sensing pathway, which initiates IFN production.
Activated caspases attenuate this response. Phar-
macological caspase inhibition or genetic deletion
of caspase-9, Apaf-1, or caspase-3/7 causes dying
cells to secrete IFN-b. In vivo, this precipitates an
elevation in IFN-b levels and consequent hematopoi-
etic stem cell dysfunction, which is corrected by loss
of Bak and Bax. Thus, the apoptotic caspase
cascade functions to rendermitochondrial apoptosis
immunologically silent.
INTRODUCTION
Caspases are a family of 12 cysteinyl aspartate-specific prote-
ases traditionally classified as inflammatory or apoptotic (McIl-
wain et al., 2013). Inflammatory caspases (caspase-1, -4, -5,
and -12 in humans) mediate innate immune responses by
cleaving precursors of proinflammatory cytokines such as IL-C1b and IL-18, thereby facilitating their secretion. The apoptotic
caspases (caspase-3, -6, -7, -8, and -9) play a role in the regula-
tion of programmed cell death.
Apoptosis comprises two convergent pathways: the intrinsic
and extrinsic (Youle and Strasser, 2008). The intrinsic pathway
is controlled by the BCL-2 family of proteins, which is divided
into three groups. The first contains prodeath BAK and BAX,
the essential effectors of the pathway. Second are the pro-
survival proteins (BCL-2, BCL-XL, BCL-W, MCL-1, and A1),
whose function is to prevent activation of BAK and BAX by
physically restraining them and by sequestering a third group
of BCL-2 family members, the prodeath ‘‘BH3-only’’ proteins
(e.g., BIM and BID). In a healthy cell, prosurvival proteins
keep BAK and BAX in check. Apoptotic signals trigger the
BH3-only proteins to activate BAK/BAX. The latter induce
mitochondrial outer-membrane permeabilization (MOMP),
facilitating the efflux of factors, including cytochrome c, into
the cytoplasm. Cytochrome c forms the apoptosome complex
with APAF-1 and the inactive zymogen of the initiator caspase,
caspase-9. This results in the activation of caspase-9, which
then triggers the rest of the caspase cascade, culminating
in activation of the effector caspases, caspase-3 and cas-
pase-7.
The purpose of the caspase cascade remains an enigma. It
mediates many of the hallmarks of apoptosis in vitro, such as
DNA fragmentation and phosphatidylserine (PS) exposure, but
is largely dispensable for the apoptotic death and clearance
of cells in vivo. The hematopoietic system is a good example:
Bak/ Bax/ mice exhibit a massive accumulation of mature
blood cells, whereas mice with an Apaf-1/, Casp9/, or
Casp3/ Casp7/ hematopoietic system show no significant
perturbations in blood cell number (Lakhani et al., 2006; Linds-
ten et al., 2000; Marsden et al., 2002). This dichotomy can beell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc. 1549
explained by the fact that the ‘‘point of no return’’ in apoptosis
is BAK/BAX-mediated mitochondrial damage. Cells lacking
BAK and BAX are resistant to a wide range of apoptotic stimuli;
they do not exhibit cytochrome c release or caspase activation
and are able to maintain clonogenicity (i.e., they can survive
and generate viable progeny) (Lindsten et al., 2000; Wei et al.,
2001). In contrast, Apaf-1- or caspase-deficient cells exhibit
only short-term resistance to apoptotic stimuli and do not retain
clonogenic potential (Ekert et al., 2004; Marsden et al., 2002;
van Delft et al., 2010). Thus, although clearly capable of accel-
erating apoptosis, these and many other studies indicate that
the apoptotic caspase cascade is not required for death to
occur.
This raises important questions as to why caspase-deficient
mice exhibit phenotypic abnormalities. For example, loss of
Apaf-1, caspase-9, or caspase-3 results in lethality associated
with large ectopic cell masses in the forebrain (Kuida et al.,
1996, 1998; Yoshida et al., 1998), and the hematopoietic stem
cell (HSC) compartment is expanded in the absence of cas-
pase-3 (Janzen et al., 2008). Although this suggests an accu-
mulation of cells otherwise destined to die, in both cases, the
evidence points to a more complex mechanism. In the brain,
controversy exists as to the extent of cell death in mice lacking
the caspase cascade, and recent studies indicate that changes
in morphogen gradients may underpin aberrant forebrain devel-
opment (Honarpour et al., 2001; Nonomura et al., 2013; Oppen-
heim et al., 2001).
HSCs present a similar conundrum. HSC survival is governed
by BCL-2 family proteins. Deletion of prosurvival Mcl-1 leads to
their death, whereas overexpression of Bcl-2 increases their
number (Domen et al., 2000; Opferman et al., 2005). This has
led to a model whereby a proportion of HSCs undergo apoptosis
during the normal course of hematopoiesis; hence, a reduction in
apoptosis is proposed to lead to accumulation of HSCs in vivo
(Orelio and Dzierzak, 2007). The expansion of HSCs observed
in caspase-3-deficient mice would accord with this notion.
Intriguingly, however, the evidence suggests that, rather than
accumulating through failure to die, Casp3/ HSCs proliferate
due to abnormalities in cytokine signaling (Janzen et al., 2008),
suggesting potential non-cell death roles for the apoptotic cas-
pase cascade. In fact, apoptotic caspases are increasingly impli-
cated in other cellular processes such as differentiation (Yi and
Yuan, 2009). In some cases, these roles are a byproduct of, or
are associated with, apoptosis; in others, they appear to be
‘‘nonapoptotic’’ in nature.
Here, we show that the caspase cascade functions during
apoptosis to prevent dying cells from producing type I inter-
feron (IFN). Bak- and Bax-mediated mitochondrial damage
triggers the release of mitochondrial DNA (mtDNA), which is
recognized by the cGAS/STING-mediated cytosolic DNA
sensing pathway. In the absence of the apoptotic caspases,
this leads to the induction of IFN-b transcription and IFN-b
secretion by the dying cell. Loss of the caspase cascade
leads to elevated IFN-b levels in vivo. This feeds back to,
and has a profound impact on, the HSC compartment, which
is highly sensitive to the effects of type I IFN. Thus the
apoptotic caspase cascade regulates the immunological
impact an apoptotic cell has on the host by preventing dam-1550 Cell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc.age-associated molecular pattern (DAMP) signaling induced
by mtDNA.
RESULTS
HSC Expansion and Dysfunction in the Absence of
Caspase-9
To define the requirement for the intrinsic apoptosis pathway
(Figure 1A) in HSC homeostasis, we generated mice lacking
Bak and Bax or caspase-9. Because these animals die postna-
tally, we first profiled the HSC-containing lineage Sca1+ Kit+
(LSK) population in fetal livers at embryonic (E) day 13.5. Relative
to wild-type (WT) counterparts, the proportion of LSKs in Bak/
Bax/ fetal livers was unchanged (Figures 1B and 1C). In
contrast, LSKs were increased 5-fold in Casp9/ fetal livers.
To establish whether this was hematopoietic cell intrinsic, we
transplanted fetal liver cells (FLCs) into lethally irradiated WT
recipients. 12–16 weeks posttransplantation, a small but statis-
tically significant increase in LSKs was observed in mice that
received Bak/ Bax/ FLCs (Figures 1D and 1E). Recapitu-
lating the situation in the fetal liver, the bone marrow of mice re-
constituted with Casp9/ cells contained 5-fold more LSKs
than those transplanted with WT cells. Collectively, these data
suggested that HSC numbers are expanded in the absence of
caspase-9. This was a counterintuitive result, given that Bak
and Bax are the critical mediators of the intrinsic apoptosis
pathway, whereas the downstream caspase cascade is thought
to be dispensable for cell death.
To examine HSC function, WT, Bak/ Bax/, or Casp9/
fetal liver test cells were mixed 50:50 with WT competitor cells
and transplanted into lethally irradiatedWT recipients (Figure 1F).
16 weeks posttransplant, the contribution of Bak/ Bax/ cells
to peripheral blood B and T lymphocytes, myeloid cells, and
bone marrow LSKs significantly outweighed that of WT compet-
itor cells (Figures 1G and S1A available online). In contrast,
Casp9/ peripheral blood B and T lymphocytes, myeloid cells,
and bone marrow LSKs were present in equal numbers to WT
competitors, suggesting that, despite the aberrant LSK profile,
the Casp9/ fetal liver contains either (1) normal numbers of
HSCs or (2) more HSCs than WT, but they are functionally
impaired. We therefore tested the self-renewal capacity of
HSCs by harvesting bone marrow from primary recipients and
transplanting it into secondary recipients (Figures 1H, 1I, and
S1B). In contrast to WT and Bak/ Bax/ cells, Casp9/
bone marrow exhibited a profoundly reduced contribution to pe-
ripheral blood B and T lymphocytes, myeloid cells, and bone
marrow LSKs at 16 weeks post-secondary transplantation (Fig-
ure 1I), indicating that HSC function is severely compromised in
the absence of caspase-9.
HSC Dysfunction in Caspase-9-Deficient Mice Is Cell
Extrinsic
To establish whether LSK expansion in Casp9/ mice was
intrinsic to the LSK population itself, we generated mixed bone
marrow chimeras by transplanting WT or Casp9/ E13.5 FLCs
with WT filler FLCs into lethally irradiated recipients. Consistent
with our previous observations, 12–16 weeks later, we observed
an expansion of Casp9/ LSKs in the WT:Casp9/ chimeras.
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Figure 1. Deficiency of Caspase-9, but Not Bak and Bax, Impairs Hematopoietic Stem Cell Function
(A) The intrinsic apoptosis pathway.
(B) Representative plots of LSK cell frequency in E13.5 fetal livers (gates display percentage of Lin).
(C) FACS analysis of LSKs in WT (n = 9), Bak/ Bax+/+ (n = 5), Bak/ Bax/ (n = 7), and Casp9/ (n = 10) E13.5 fetal livers.
(D) Bone marrow cellularity in recipients of WT (n = 15), Bak/ Bax/ (n = 8), and Casp9/ (n = 9) FLCs 12–16 weeks posttransplant.
(E) Donor-derived LSK cells in WT (n = 15), Bak/ Bax/ (n = 8), and Casp9/ (n = 9) bone marrow chimeras 12–16 weeks posttransplant.
(F) Fetal liver competitive transplantation assay.
(G) Proportion of CD45.2+ peripheral blood B lymphocytes, T lymphocytes, myeloid cells, and bone marrow LSK cells 16 weeks after competitive transplantation
(n = 3–4 E13.5 test-CD45.2+ fetal livers per genotype and three recipients per donor mix). See also Figure S1.
(H) Secondary transplantation assay.
(I) Donor-CD45.2+ contribution to peripheral blood B lymphocyte, T lymphocyte and myeloid cells, and bone marrow LSK cells of 1 and 2 recipients 16 weeks
posttransplant (n = 3–5 donor fetal livers per genotype and 2–3 recipients per donor bone marrow) See also Figure S1.
Means were compared to WT using a one-way ANOVA with Bonferroni correction. Data represent the mean ± SEM. *p% 0.05, **p% 0.01, and ***p% 0.005.Strikingly, WT LSK numbers were also significantly increased
relative to those in WT:WT chimeras (Figure 2A). Their Sca1
expression profile resembled that of Casp9/ Lin Kit+ cells
(Figure 2B). Thus, WT LSKs expand in the presence of cas-
pase-9-deficient hematopoietic cells, suggesting that HSC
expansion in Casp9/ mice is driven by cell-extrinsic factors.
Caspase-9-Deficient HSPCs Exhibit a Type I Interferon
Response Signature
We therefore analyzed the gene expression profile of Lineage
Kit+ CD45.2+ hematopoietic stem and progenitor cells (HSPCs)
harvested primary bone marrow chimeras. 495 genes (corre-
sponding to 602 probes) were significantly upregulated in
Casp9/ HSPCs (Figure 2C and Table S1 available online),
with 275 genes (corresponding to 346 probes) differentially
expressed (DE) in Bak/ Bax/ HSPCs. In Casp9/ HSPCs,
gene set enrichment analysis using Camera identified enrich-
ment for multiple type I IFN response signatures that were not
apparent in Bak/ Bax/ HSPCs (Figures 2D and 2E). The
top ten upregulated genes in Casp9/ HSPCs by fold changeCwere all type I IFN targets (Table S1). Quantitative PCR (qPCR)
analysis of canonical type I IFN-stimulated genes (ISGs) con-
firmed their upregulation relative to WT in Casp9/ FLCs and
bone marrow cells (Figures 2F and 2G). We therefore examined
levels of the type I IFNs, IFNa and IFN-b, in the serum of primary
transplant recipients. Whereas IFNa was undetectable in all
genotypic classes, we observed significantly elevated IFN-b in
mice reconstituted with Casp9/, but not Bak/ Bax/, cells
(Figure 2H).
HSC Expansion in Caspase-9-Deficient Mice Is Caused
by Type I Interferons
Type I IFNs have been shown to induce HSC proliferation, lead-
ing to functional exhaustion in vivo (Essers et al., 2009; Sato
et al., 2009). We therefore generated mice doubly deficient
for caspase-9 and the type I IFN receptor (Ifnar1). Although
loss of Ifnar1 did not rescue postnatal lethality of Casp9/
mice (data not shown), deletion of Ifnar1 prevented LSK expan-
sion in Casp9/ fetal livers (Figures 3A and 3B). Next, bone
marrow chimeras were generated by reconstituting recipientsell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc. 1551
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Figure 2. Loss of Caspase-9 Results in Elevated Type I Interferon In Vivo
(A) FACS analysis of mixed bone marrow chimeras 12–16 weeks posttransplant of WT (CD45.2+) or Casp9/ (CD45.2+) with WT ‘‘bystander’’ (CD45.1+CD45.2+)
E13.5 FLCs into lethally irradiated CD45.1+ recipients. Number of donor-derived bone marrow LSK cells from both fractions is displayed (n = 8 mixed bone
marrow chimeras per genotype from 3–4 fetal livers per genotype). Means of WT (CD45.1+CD45.2+) ‘‘bystander’’ cells were compared using a two-tailed t test.
(B) Sca1 expression on LinKit+ bone marrow cells from mixed bone marrow chimeras.
(C) Scatterplot of differentially expressed probes in microarray analysis of WT, Casp9/, and Bak/ Bax/ LinKit+CD45.2+ bone marrow cells. See also
Table S1.
(D) Top ten gene sets (ranked by p value) from Gene Set Enrichment Analysis (GSEA) of Casp9/ in (C) (gray indicates type I IFN signatures).
(E) Top ten gene sets (ranked by p value) from GSEA of Bak/ Bax/ in (C).
(F andG) Real-time qPCR analysis of type I ISGs in fetal liver (F) and bonemarrow cells (G) (n = 3–4 E13.5 fetal livers and 3–4 bonemarrow chimeras per genotype).
(H) IFN-b protein in serum of WT (n = 6), Casp9/ (n = 6), and Bak/ Bax/ (n = 8) bone marrow chimeras.
Unless indicated, means were compared toWT using a one-way ANOVA with Bonferroni correction. Data represent the mean ± SEM. *p% 0.05, **p% 0.01, and
***p% 0.005.with Ifnar1/Casp9+/+, Ifnar1+/+ Casp9/, or Ifnar1/Casp9/
 FLCs. 16 weeks posttransplantation, recipients of Ifnar1+/+
Casp9/ cells exhibited a 5-fold increase in LSKs relative to
mice that received Ifnar1/ Casp9+/+ cells (Figures 3C and
3D). In contrast, LSK numbers in Ifnar1/ Casp9/ chimeras
were normal. Furthermore, deletion of Ifnar1 restored the ability
of Casp9/ HSCs to engraft the host and contribute to all major
lineages upon secondary transplantation (Figures 3E and 3F).
Collectively, our data indicate that loss of caspase-9 in vivo leads
to production of IFN-b, which feeds back to the HSC compart-
ment, resulting in loss of self-renewal capacity.1552 Cell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc.Apoptotic Mouse and Human Cells Produce Type I IFN
When Caspases Are Inhibited
Activation of the apoptotic caspase cascade is impaired in the
absence of caspase-9 (Li et al., 1997). We hypothesized that he-
matopoietic cells undergoing caspase-inhibited apoptosis might
be the source of IFN-b. To test this, we treated WT murine sple-
nocytes with the proapoptotic BH3 mimetic drug ABT-737,
which targets the prosurvival proteins Bcl-xL and Bcl-2 (Olters-
dorf et al., 2005). ABT-737 induced caspase activation and cell
death in splenocytes (Figures 4A and 4B). No IFN-b was de-
tected in culture media of cells treated with ABT-737 alone. In
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Figure 3. Type I Interferon Mediates the Hematopoietic Stem Cell Dysfunction Associated with Caspase-9 Loss
(A) Representative plots of LSK cell frequency in E13.5 fetal livers (gates display percentage of Lin).
(B) FACS analysis of LSKs in Ifnar1/ Casp9+/+ (n = 6), Ifnar1+/+ Casp9/ (n = 4), and Ifnar1/ Casp9/ (n = 6) E13.5 fetal liver.
(C) Bone marrow cellularity from Ifnar1/ Casp9+/+ (n = 8), Ifnar1+/+ Casp9/ (n = 4), and Ifnar1/ Casp9/ (n = 5) bone marrow chimeras, 16 weeks
posttransplant.
(D) Number of donor-derived LSK cells from Ifnar1/Casp9+/+ (n = 7), Ifnar1+/+Casp9/ (n = 4), and Ifnar1/Casp9/ (n = 5) bonemarrow chimeras, 16 weeks
posttransplant.
(E) Donor-CD45.2+ contribution to the peripheral blood B lymphocyte, T lymphocyte, myeloid cells, and bonemarrow LSK cells of 1 and 2 recipients at 16weeks
posttransplant. Ifnar1/ Casp9+/+ (n = 4), Ifnar1+/+ Casp9/ (n = 3), and Ifnar1/Casp9/ (n = 4) donor fetal livers per genotype and three recipients per donor
bone marrow.
(F) Plots of representative analysis of donor contribution to 2 recipient lymphoid lineages in (E).
Means were compared to WT using a one-way ANOVA with Bonferroni correction. Data represent the mean ± SEM. *p% 0.05, **p% 0.01, and ***p% 0.005.contrast, when apoptosis was triggered in the presence of the
pan-caspase inhibitor Q-VD-Oph, IFN-b was produced (Fig-
ure 4C). To test whether this mechanism is conserved between
mice and humans, peripheral blood mononuclear cells (PBMCs)
were isolated from the blood of five healthy adult donors and
treated with ABT-737. Caspase-3/7 activation and loss of cell
viability was observed over 24 hr (Figures 4D and 4E). Upon co-
incubation with ABT-737 and Q-VD-Oph, IFN-b secretion was
observed in all five human PBMC samples (Figure 4F). These
data demonstrated that, in both human and murine hematopoi-
etic cells, caspase-inhibited apoptosis results in the production
of IFN-b.
Apoptotic MEFs Produce Type I IFNWhen Caspases Are
Inhibited
To better examine the role of the intrinsic apoptosis pathway, we
utilized immortalized mouse embryonic fibroblasts (MEFs). WT
MEFs are dependent on the prosurvival proteins Mcl-1 and
Bcl-xL for survival (Figure 5A). MEFs lacking Mcl-1 undergo
Bak- and Bax-mediated apoptosis in response to ABT-737
(van Delft et al., 2006). We therefore treated multiple Mcl1/
MEF lines with increasing concentrations of ABT-737 and coin-
cubated them with either Q-VD-Oph or another pancaspase
inhibitor, z-VAD.fmk. ABT-737 treatment of Mcl1/ MEFs
induced caspase-3/7 activity and cell death (Figures 5B and
5C). Coincubation with either z-VAD.fmk or Q-VD-Oph blocked
caspase activation and prevented loss of viability. Although
undetectable in supernatant from Mcl1/ MEFs treated withCABT-737 or caspase inhibitor alone, IFN-b was induced when
ABT-737 (or other apoptotic stimuli) (Figure S2) was combined
with z-VAD.fmk or Q-VD-Oph (Figure 5D). Upregulation of
Ifnb1, the gene encoding IFN-b, was evident 4 hr posttreatment
(Figure 5E). These data demonstrate that nonhematopoietic cells
also produce IFN-b when undergoing caspase-inhibited
apoptosis and implicate Bak and Bax as the initiators of the
signal that triggers IFN-b production.
The Apoptotic Caspase Cascade Suppresses Bak/Bax-
Mediated Type I IFN Production
To confirm whether Bak and Bax activation induces IFN-b
production, we triggered mitochondrial apoptosis in WT,
Casp9/, and Bak/ Bax/Casp9/MEF lines by combining
ABT-737 treatment with expression of BimS2A, which targets
Mcl-1 (Lee et al., 2008). Expression of BimS4E, an inert form
of Bim, served as a negative control. Casp3/ Casp7/ MEF
lines were included to determine whether deletion of the
effector caspases causes IFN production. In WT cells express-
ing BimS2A, ABT-737 treatment induced a 3-fold increase in
caspase activity and an 75% loss of viability (Figures 5F–5H).
In contrast, both Casp9/ and Bak/ Bax/ Casp9/ cells
were resistant to BimS2A + ABT-737. Analysis of the supernatant
demonstrated abundant IFN-b secretion by Casp9/ and
Casp3/ Casp7/ cells treated with BimS2A + ABT-737, but
not WT or Bak/ Bax/ Casp9/ counterparts (Figures 5I
and S3). These data demonstrated that, in vitro, induction of
Bak- and Bax-mediated apoptosis stimulates type I IFNell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc. 1553
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Figure 4. Apoptotic Hematopoietic Cells Produce Type I Interferon When Caspases Are Inhibited
(A) Viability of murine splenocytes treated with ABT-737 ± 20–30 mM Q-VD-OPh (QVD) for 24 hr.
(B and C) (B) Caspase activity and (C) IFN-b in culture supernatant after 24 hr of treatment (n = 4 mice). Means were compared using a two-tailed t test. Data
represent the mean ± SEM. *p% 0.05, **p% 0.01, and ***p% 0.005.
(D) Percentage of viable human PBMCs as quantitated by ATP levels (CellTiterGlo) after 24 hr of treatment with ABT-737 and coincubation with 20–30 mMQ-VD-
OPh (QVD).
(E) Bar graphs of caspase activity after 6 hr and (F) IFN-b in culture supernatant after 24 hr (n = 5 healthy donor blood samples). Representative of two independent
experiments.production when either the apoptotic initiator (caspase-9) or
effector (caspase-3/7) caspases are inactivated.
We reasoned that eliminating Bak and Bax would remove the
stimulus for IFN-b production in caspase-deficient mice. To test
this, we generated Casp9/, Apaf1/, Casp3/, Casp3/
Casp7/, and Bak/ Bax/ Casp9/ bone marrow chimeras.
16weeks posttransplantation, LSKswere increased in recipients
of Apaf1/, Casp9/ or Casp3/ Casp7/ cells, demon-
strating that inhibition of the apoptotic caspase cascade at either
the apoptosome or effector stage triggers LSK expansion (Fig-
ures 5J and 5K). In contrast, the LSK profile in Bak/ Bax/
Casp9/ chimeras was unchanged. Thus, in the absence of
Bak- and Bax-mediated apoptosis, deletion of caspases does
not cause LSK expansion. Accordingly, IFN-b levels in Bak/
Bax/ Casp9/ chimeras were equivalent to WT, and no upre-
gulation of type I IFN response genes was apparent (Figures 5L
and 5M). Secondary bone marrow transplants confirmed that
loss of Bak/Bax-mediated apoptosis also rescued HSC function,
with Bak/ Bax/ Casp9/ bone marrow efficiently engrafting
the host and contributing to the LSK compartment and all major
lineages (Figure 5N). Thus, deletion of Bak andBax prevents IFN-
b production and HSC dysfunction in mice lacking a functional
apoptotic caspase cascade.
Dying Cells Upregulate Type I IFN Production in a
Cell-Intrinsic Manner
We next examined whether apoptotic cells secrete IFN-b in
a cell-intrinsic manner. Ifnar1/ Casp9/ MEFs were trans-
duced with BimS2A-GFP or BimS4E-GFP and co-plated with
unmanipulated Ifnar1/ MEFs (Figures 6A and 6B). Ifnar1-defi-
cient cells were utilized to eliminate paracrine/autocrine effects
of IFN-b. Cocultures were treated with ABT-737, which induced1554 Cell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc.apoptosis in the Ifnar1/ Casp9/ BimS2A-GFP cells, but not
the other three cell populations. Subsequently, GFP+ (apoptotic
or nonapoptotic) and GFP (bystander) cells were sorted, and
expression of Ifnb1 was analyzed by qPCR. Relative to healthy
bystanders, a significant upregulation of Ifnb1 mRNA was
observed in apoptotic, but not nonapoptotic, cells (Figures 6B
and 6C). When using WT (rather than Ifnar1/) bystanders,
type I IFN response genes were strongly induced in bystanders
cocultured with apoptotic cells (Figure 6D), indicating that cells
undergoing caspase-inhibited apoptosis actively transcribe
Ifnb1 and secrete bioactive IFN-b.
Apoptotic IFN Production Is Driven by
Mitochondrial DNA
Considering the mechanism by which Bax and Bax stimulate
a cell to produce type I IFN, we reasoned that release of a
mitochondrial factor into the cytoplasm could be the initiating
event. In the context of microbial invasion, type I IFNs are
induced by a range of pathogen-associated molecular patterns
(PAMPs). Viral nucleic acids are an important, and potent,
example. Their presence is detected by cytosolic receptors
that activate signaling cascades leading to the upregulation
of IFN transcription (Paludan and Bowie, 2013). We hypothe-
sized that Bak- and Bax-mediated damage to mitochondria
may cause the release of mtDNA and that the latter would
act as a DAMP capable of recognition by the dying cell’s
innate nucleic acid sensors. We therefore generated mtDNA-
depleted cells (so-called ‘‘r0’’ cells) by culturing Mcl1/
MEFs in ethidium bromide (King and Attardi, 1989). qPCR anal-
ysis revealed a near-complete absence of mtDNA after three
passages (Figures 6E and S4). Expression profiling of r0 cells
demonstrated that 28 genes (corresponding to 42 probes)
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Figure 5. Disabling Caspases Downstream of Bak and Bax Triggers Type I IFN Production
(A) Schematic diagram of the manipulation of intrinsic apoptosis in MEFs.
(B–D) (B) Viability of MEFs treated with ABT-737 ± 20–30 mM of Q-VD-Oph (QVD) or z-VAD.fmk (zVAD) for 24 hr, (C) bar graphs of caspase activity after 6 hr, and
(D) IFN-b in supernatant after 24 hr (n = 9 independent MEF lines). Means were compared using a two-tailed t test. See also Figure S2.
(E) Real-time qPCR analysis of Ifnb1 induction in Mcl1/ MEFs (n = 3 independent MEF lines). Means were compared using a two-tailed t test.
(F and G) (F) Viability of MEFs expressing Bims2A or Bims4E and treated with ABT-737 for 20–24 hr and (G) caspase activity after 6 hr.
(H and I) (H) Immunoblot of lysates of MEFs treated with ABT-737 (1 mM) for 4 hr and (I) bar graph of IFN-b in supernatant after 20–24 hr (n = 3 independent MEF
lines per genotype). See also Figures S2 and S3.
(J) Bone marrow cellularity fromWT (n = 22), Bak/ Bax/ (n = 8), Apaf1/ (n = 5), Casp9/ (n = 11), Casp3/ (n = 13), Casp3/ Casp7/ (n = 7), and Bak/
Bax/ Casp9/ (n = 9) bone marrow chimeras.
(K) Number of donor-derived LSK cells fromWT (n = 22), Bak/ Bax/ (n = 8), Apaf1/ (n = 5),Casp9/ (n = 11),Casp3/ (n = 13), Casp3/Casp7/ (n = 7),
and Bak/ Bax/ Casp9/ (n = 9) bone marrow chimeras.
(L) IFN-b in serum of WT (n = 10), Casp9/ (n = 5), Casp3/ (n = 5), Casp3/ Casp7/ (n = 4), and Bak/ Bax/ Casp9/ (n = 7) bone marrow chimeras. Not
done, N.D.
(M) Real-time qPCR analysis of type I ISGs in bone marrow cells (n = 3–4 bone marrow chimeras per genotype). Means were compared using a two-tailed t test.
(N) Donor-CD45.2+ contribution to the peripheral blood B lymphocyte, T lymphocyte, myeloid cells, and bone marrow LSK cells of 1 and 2 recipients 16 weeks
posttransplant (n = 3 donor fetal livers per genotype and 3 recipients per donor bone marrow).
Unless otherwise indicated, means were compared toWT using a one-way ANOVAwith Bonferroni correction. Data represent the mean ± SEM. *p% 0.05, **p%
0.01, and ***p% 0.005.
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Figure 6. mtDNA Triggers Type I IFN Production during Caspase-Inhibited Apoptosis
(A) Representative plots of infection efficiency of the MEFs used in (B–D).
(B and C) Real-time qPCR analysis of nonapoptotic (expressing Bims4E, B) and apoptotic (expressing Bims2A, C) MEFs and their respective Ifnar1
/ bystander
from cocultures after treatment with ABT-737 (500 nM) for 18–20 hr (data combined from three experiments, with two independent MEF lines per genotype).
mRNA expression is shown relative to two independent housekeeping genes, tbp and gapdh.
(D) Real-time qPCR analysis of WT bystanders from cocultures after treatment with ABT-737 for 18–20 hr (data combined from two experiments, with two in-
dependent MEF lines/genotype).
(E) Real-time qPCR analysis of mtDNA content from Mcl1/ MEFs cultured in ethidium bromide to generate mtDNA-depleted (r 0) MEFs (used in F–J).
Representative image of MEFs stained with PicoGreen nucleic acid stain. Arrows indicate mtDNA. Scale bars, 10 um. See also Figure S4.
(F) Scatterplot of differentially expressed probes from microarray analysis of Mcl1/ r 0 MEFs compared to their respective parental Mcl1/ MEF. (n = 3 in-
dependent MEF lines). Chromosome M, ChrM. See also Table S2.
(G) Table of a selected set of type I IFN response genes from analysis in (F).
(H) Bar graph of IFN-b in the supernatant of r 0 and parental MEFs transfected with Poly(I:C)(HMW) (n = 3 independent MEF lines).
(I–K) (I) Bar graphs of the viability of r0 and parental MEFs treated with ABT-737 ± 20–30 mM of Q-VD-Oph (QVD) for 24 hr, (J) caspase activity after 6 hr, and (K)
IFN-b in supernatant after 24 hr (n = 4 independent MEF lines).
Means were compared using a two-tailed t test. Data represent the mean ± SEM. *p% 0.05, **p% 0.01, and ***p% 0.005.were downregulated and 61 genes (corresponding to 82
probes) were upregulated (Figure 6F and Table S2). 18 probes
corresponding to 9 mitochondrially encoded genes were pre-1556 Cell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc.sent on the array. These were the most downregulated genes
in r0 cells (Camera p value = 0.0095). Gene set analysis using
Camera detected no significant enrichment for any of the c2
expression signatures (data not shown). In addition, a subset of
known type I IFN response genes was not significantly downre-
gulated in r0 cells (Figure 6G, Camera p value for downregula-
tion = 0.45). Consistent with there being no functional impair-
ment of IFN response pathways, r0 cells responded normally
when transfected with poly(I:C) (Figure 6H). Treatment of
Mcl1/ r0 cells with ABT-737 resulted in caspase activation
and a loss of viability similar in magnitude to that exhibited
by the parental lines (Figures 6I and 6J). In the presence of
Q-VD-Oph, IFN-b production was observed in the parental,
but not r0, cells (Figure 6K). These data indicate that mtDNA
is the trigger for IFN production downstream of Bak- and
Bax-mediated mitochondrial damage.
Bak/Bax-Mediated mtDNA Release Triggers cGAS/
STING-Dependent IFN Production
Two major pathways that mediate type I IFN production in
response to intracellular microbial DNA have been described
(Paludan and Bowie, 2013). The first is initiated by Toll-like re-
ceptor 9 (Tlr9) recognition of DNA localized to endosomes, which
triggers Myd88 signaling. Deletion of Myd88 in Casp9/ chi-
meras failed to normalize serum IFN-b levels and did not prevent
LSK expansion (Figure S5), suggesting that mtDNA-induced
IFN-b production does not require the Tlr-mediated endosomal
recognition pathway. The second is the stimulator of interferon
genes (STING) pathway (Barber, 2014). It is triggered when
DNA binds to cyclic GMP-AMP synthase (cGAS), thereby cata-
lyzing production of cyclic GMP-AMP dinucleotide (cGAMP),
which binds to and activates STING. Activated STING induces
type I IFN transcription via the Tbk1-Irf3 signaling axis. We
treated splenocytes from WT and STING-deficient mice with
ABT-737 in the presence or absence of Q-VD-Oph. ABT-737
induced apoptotic caspase activation and cell death in WT and
STING/ cells with similar kinetics (Figures 7A and 7B). Coincu-
bation with Q-VD-Oph triggered IFN-b secretion by WT, but not
STING/, cells (Figure 7C).
To further dissect the requirement for the STING pathway, we
derived MEFs from STING/ mice and generated MEF lines
lacking cGAS and Irf3 by CRISPR/Cas9-mediated gene target-
ing. All lines underwent apoptosis in response to ABT-737
and BimS2A (Figures 7D and 7E). WT cells produced IFN-b
when coincubated with Q-VD-Oph. In contrast, cGASCRISPR/,
STING/, and Irf3CRISPR/ cells did not (Figure 7F). The re-
quirement for Tbk1 was examined by pretreatingMcl-1-deficient
MEFs with the Tbk1 inhibitor MRT-67307. Mcl1/ cells under-
going caspase-inhibited apoptosis secreted IFN-b (Figures 7G
and 7H). Addition of MRT-67307 suppressed IFN-b production
by dying cells (Figure 7I). These data demonstrate that cas-
pase-inhibited apoptosis triggers cGAS/STING/Tbk1/Irf3-medi-
ated IFN-b production.
Recent evidence indicates that cGAS is activated via a direct
interaction with cytosolic DNA (Civril et al., 2013; Sun et al.,
2013). To establish whether mtDNA interacts with cGAS during
caspase-inhibited apoptosis, we immunoprecipitated cGAS
from Mcl1/ MEFs treated with ABT-737 and Q-VD-Oph and
utilized qPCR analysis to detect coprecipitated DNA. Although
there was no mtDNA enrichment when cGAS was immunopre-
cipitated from untreated cells, a significant enrichment forCmtDNA, but not genomic DNA, was observed in cells treated
with ABT-737 and Q-VD-Oph (Figure 7J). Collectively, these
data indicate that mtDNA is released, binds to, and activates
cGAS during caspase-inhibited apoptosis.
DISCUSSION
Role of the Intrinsic Apoptosis Pathway in HSC
Homeostasis
Deletion of Bak and Bax had no impact on the number of im-
munophenotypic HSCs in the fetal liver, suggesting that the
intrinsic apoptosis pathway is dispensable for HSC homeo-
stasis during development. Upon transplantation, recipients of
Bak/ Bak/ FLCs exhibited a statistically significant 2-fold in-
crease in bone marrow LSK number. This increase is similar to
that reported for mice overexpressing Bcl-2 (Domen et al.,
2000) and supports a role for the intrinsic pathway in regulating
adult HSC homeostasis. However, a simpler explanation might
be that HSCs lacking Bak and Bax are more resistant to the
stresses of transplantation. Consistent with this, Bak/ Bak/
FLCs outcompeted WT counterparts in mixed transplants.
Similar effects have been reported for HSCs lacking Bim (Labi
et al., 2013). Thus, the extent to which death via the intrinsic
apoptosis pathway shapes the HSC pool at steady state remains
to be determined. It may be that programmed cell death does
not represent a significant fate for HSCs. Alternatively, other
cell death modalities such as the extrinsic apoptosis pathway
or necroptosis might contribute to HSC homeostasis.
Apoptotic versus Nonapoptotic Roles for Apoptotic
Caspases
Apoptotic caspases have been ascribed a number of functions
beyond the internal demolition of dying cells. Some of these
(e.g., prostaglandin-induced tumor cell repopulation [Huang
et al., 2011] and AMPA receptor internalization [Li et al.,
2010b]) appear to be a byproduct of apoptotic cell death. Others
(e.g., iPS cell reprogramming [Li et al., 2010a] and microglia acti-
vation [Burguillos et al., 2011]) are thought to represent ‘‘nona-
poptotic’’ roles for caspases. Our genetic experiments, both
in vitro and in vivo, demonstrate that, in suppressing IFN produc-
tion, the apoptotic caspases play an apoptotic role, i.e., function
downstream of Bak and Bax. Unless Bak and Bax are activated,
mtDNA is not released, and caspases are not required to atten-
uate mtDNA-induced DAMP signaling. This has two important
implications. First, blocking the apoptotic caspase cascade
during apoptosis triggers the production of IFN-b, a potentially
significant confounding experimental factor. This should be
considered whenever the apoptotic caspase cascade is geneti-
cally or pharmacologically manipulated. Perturbations in type I
IFN signaling may explain some of the published biological roles
for caspases. Second, the fact that caspase-deficient mice pre-
sent with a dramatic increase in LSKs, whereas Bak/ Bax/
animals do not, initially suggested that caspases play a ‘‘nona-
poptotic’’ role in HSCs. However, the subsequent experiments
with Bak/ Bax/ Casp9/ cells and bone marrow chimeras
demonstrated that the phenotype is dependent on Bak/Bax
activation. This highlights the importance of establishing whether
apoptotic caspase activation in a given setting is the result ofell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc. 1557
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Figure 7. mtDNA Release into the Cytosol Triggers cGAS-STING-Tbk1-Irf3-Mediated Type I Interferon Production
(A–C) (A) Viability of murine splenocytes treated with ABT-737 ± 20–30 mM Q-VD-OPh (QVD) for 24 hr, (B) caspase activity after 6 hr, and (C) IFN-b in culture
supernatant after 24 hr (n = 4 mice per genotype). Means were compared to WT using a one-way ANOVA with Bonferroni correction.
(D–F) (D) Viability of MEFs treated with ABT-737 ± 20–30 mM Q-VD-OPh (QVD) for 24 hr, (E) caspase activity after 6 hr, and (F) IFN-b in culture supernatant after
24 hr (n = 3 independent MEF lines per genotype, or 3 independent CRISPR/Cas9-targeted MEF clones). Means were compared to WT using a one-way ANOVA
with Bonferroni correction.
(G–I) (G) Bar graphs of the viability of Mcl1/ MEFs pretreated for 1 hr with MRT-67307 (mM) followed by ABT-737 (500 nM) ± 20–30 mM Q-VD-OPh (QVD) for
24 hr, (H) caspase activity after 6 hr, and (I) IFN-b in culture supernatant after 24 hr (n = 3 independent MEF lines).
(legend continued on next page)
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upstream mitochondrial damage or an alternative signaling
mechanism.
mtDNA Activates the STING-Dependent Cytosolic DNA
Sensing Pathway
Our data indicate that Bak/Bax-dependent mtDNA release
triggers the cGAS/STING-dependent cytosolic DNA sensing
pathway. mtDNA released during cell death has been previously
reported to provide a second signal that cooperates with signal 1
(e.g., LPS) to activate the NLRP3 inflammasome and induce IL-
1b production (Shimada et al., 2012). Whether mtDNA released
via Bak/Bax also activates the inflammasome is unclear. How-
ever, other than IFN-b, mice with a caspase-9-deficient hemato-
poietic system did not exhibit elevated proinflammatory cytokine
serum levels or any signs of systemic autoinflammatory disease
when aged to 12 months (Figure S6). This suggests that, at least
in the context of steady-state hematopoietic cell turnover, Bak/
Bax-mediated mtDNA release does not result in unbridled in-
flammasome activity when the caspase cascade is inactivated.
Whether the elevations in IFN-b caused by loss of the caspase
cascade lead to the development of autoimmune disease over
the longer term and whether perturbations in caspase activity
might contribute to human autoinflammatory/autoimmune dis-
ease remain to be established.
Mechanisms of Caspase-Mediated Suppression
of Type I IFN
During apoptosis, caspases orchestrate a global program of
cellular demolition, targeting 1,000 protein substrates (Craw-
ford and Wells, 2011). They cause DNA damage, suppress tran-
scription, shut down protein translation, and disable a host of
other essential cellular processes. Unlike genomic damage,
which is triggered by cleavage of iCAD, the inhibitor of cas-
pase-activated DNase (CAD) (Enari et al., 1998), and PS expo-
sure, which is facilitated by cleavage of Xkr8 (Suzuki et al.,
2013), it seems likely that caspase-mediated suppression of
IFN-b production (and DAMP signaling generally) is the result
of multiple redundant processes. First, the fact that apoptotic
CADCRISPR/ MEFs secrete detectable amounts of IFN-b sug-
gests that CAD-mediated genomic damage contributes to the
attenuation of gene expression (Figure S7). Second, caspase-
3/7 might cleave and inactivate a component or components
of the type I IFN production pathway. There is evidence that
IFN signaling intermediates, including Irf3, can be targeted by
caspases (Crawford et al., 2013). Third, caspase-3/7 could
mediate the degradation of mtDNA, thereby preventing its
interactionwith cGAS. Thismight occur via CAD or perhaps lyso-
somal deoxyribonuclease (DNase) II, which can digest the
genomic DNA of engulfed cells. Although the precise contribu-
tion these and other mechanisms make to suppressing IFN-b(J) Immunoprecipitation (IP) followed by PCR. Left, immunoblot of lysates taken
cGAS. Right, data represent the fold change (FC) in enrichment of DNA fragmen
MEFs or MEFs treated with ABT-737 (1 mM) and Q-VD-OPh (QVD) (30 mM) for the
primer pairs for mtDNA and two primer pairs for gDNA. The relative locations o
replicates). Means were compared between treated and untreated samples.
See also Figures S5, S6, and S7.
Unless otherwise stated, means were compared using a two-tailed t test. Data r
Cproduction in apoptotic cells remains to be established, it seems
unlikely that any one of them is solely responsible. We suggest
that caspase-mediated acceleration of cell death and suppres-
sion of DAMP signaling are inextricably linked. Both outcomes
are achieved via global cellular demolition.
Potential Crosstalk between Apoptosis and Necroptosis
Necroptosis is a regulated form of necrotic cell death mediated
by receptor-interacting protein kinase 3 (RIPK3) and the pseu-
dokinase Mlkl (Linkermann and Green, 2014). It is triggered
by prodeath ligands like TNFa and requires the inhibition or
loss of caspase-8. In vitro, necroptosis is typically induced by
TNFa and a caspase inhibitor such as z-VAD.fmk or Q-VD-
Oph. The latter are both broad-spectrum inhibitors that tar-
get caspase-8, caspase-9, and caspase-3/7 (Chauvier et al.,
2007). If necroptotic stimuli induce mitochondrial damage
and mtDNA release, our results would predict that pan-caspase
inhibition would result in IFN production by dying cells. Previ-
ous studies suggest that necroptosis triggered by TNFa, z-
VAD.fmk, and cycloheximide causes Bak/Bax-dependent mito-
chondrial damage (Irrinki et al., 2011) and that Bak/ Bax/
MEFs are partially protected from necroptotic death induced
by TNFa, Q-VD-Oph, and a Smac mimetic (TSQ) (Moujalled
et al., 2013). Given that, like TNFa, type I IFNs, in combination
with caspase inhibition, can induce necroptosis (Dillon et al.,
2014; Thapa et al., 2013), our data suggest the potential for
feed-forward effects driven by mtDNA-induced IFN production
during caspase-inhibited necroptosis.
Pharmacological Inhibition of Apoptotic Caspases
Several caspase inhibitors have undergone clinical trials. They
include the caspase-1 inhibitors VX-740 and VX-765 (Belnaca-
san) and the pan-caspase inhibitors IDN-6556 (Emricasan) and
GS-9450 (O’Brien and Dixit, 2009). To date, none have received
approval, although IDN-6556 is in ongoing trials for a number of
indications, including alcoholic hepatitis, hepatic impairment,
and islet transplantation. Evidence that VX-765 can block the py-
roptotic death of HIV-infected CD4 T cells (Doitsh et al., 2014)
has added to the hope that caspase inhibitors may yet find clin-
ical application. That study highlighted their potential as a new
class of antiviral drugs that target the host, not the virus. Our find-
ings support this notion from an entirely different angle, suggest-
ing that apoptotic caspase inhibitionmight be an effectivemeans
of amplifying endogenous IFN production. It will be interesting to
see whether patients treated with a pancaspase inhibitor exhibit
elevations in IFN-b levels.
Caspases Negatively Regulate DAMP Signaling
The traditional classification of caspases as inflammatory or
apoptotic has broken down in the last decade, as it has becomefrom Mcl1/ MEFs transduced with an expression plasmid encoding FLAG-
ts using anti-FLAG or IgG (negative control) to coprecipitate DNA in untreated
indicated time. DNA fragments were amplified by real-time qPCR using eight
f the mtDNA amplicons are shown (data are combined from two, with three
epresent the mean ± SEM. *p% 0.05, **p% 0.01, and ***p% 0.005.
ell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc. 1559
apparent that inflammatory caspases such as caspase-1 can kill
and that apoptotic caspases can mediate non-death processes.
Our findings demonstrate that caspase-9, -3, and -7 are essen-
tial negative regulators of mtDNA-induced DAMP signaling.
Although apoptotic caspases have been previously reported
to inactivate the DAMPs HMGB1 (Kazama et al., 2008) and IL-
33 (Cayrol and Girard, 2009; Lu¨thi et al., 2009), the absence of
autoinflammatory disease in caspase-9-deficient bone marrow
chimeras suggests that, at least in the context of the hematopoi-
etic system, apoptotic caspases are dispensable for their regu-
lation. Alternatively, IFN-bmay mask their effects. A very cogent
review of this subject recently proposed that mammalian cas-
pases ‘‘can be construed to act as either positive or negative
regulators of inflammation’’ (Martin et al., 2012). Given that
type I IFNs are pleiotropic in nature, possessing both inflamma-
tory and anti-inflammatory properties (Prinz and Knobeloch,
2012), our results indicate that the apoptotic caspases serve
as both.
EXPERIMENTAL PROCEDURES
Experimental Animals
All mice were backcrossed for at least ten generations on a C57BL/6 back-
ground. Apaf1/ (Yoshida et al., 1998), Bak/ (Lindsten et al., 2000), Bax/
(Lindsten et al., 2000), Casp9/ (Kuida et al., 1998), Casp3/ (Kuida et al.,
1996), Casp7/ (Lakhani et al., 2006), Ifnar1/ (Hwang et al., 1995),
Myd88/ (Adachi et al., 1998), and STING/ (Jin et al., 2011) strains have
been described. Animal procedures were approved by the Walter and Eliza
Hall Institute Animal Ethics Committee.
Cell Death Assays
Cell death was induced by exposure to ABT-737 (AbbVie), Dexamethasone
(Sigma), WEHI-539 (MedChemExpress), or Etoposide (Hospira). Where
indicated, cells were preincubated for 1 hr with MRT-67307 (Sigma) and for
15–30 min with ABT-737, followed by continuous exposure to Q-VD-Oph
(SM Biochemicals) or zVAD.fmk (R&D Systems). Cell viability was quantified
by CellTiterGlo (Promega) or flow cytometric analysis of cells excluding
5 mg/ml propidium iodide (PI) (Sigma) and, where indicated, cells also
negative for AnnexinV-FITC (InvivoGen) binding using a FACSCailbur (BD)
or LSRII (BD). Caspase activity was assayed by the addition of caspase3/
7Glo (Promega) or by immunoblotting as described in the Extended Experi-
mental Procedures.
Measurement of IFN-b
IFN-b protein was measured using the VeriKine-HS Human or Mouse Inter-
feron Beta ELISA (PBL Assay Science).
Generation of mtDNA-Depleted r0 Cells
MEFs were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO)
supplemented with 4 mM L-glutamine, 4.5 g/l glucose, 10% FCS, 100 mg/ml
sodium pyruvate, and 50 mg/ml uridine as described (Hashiguchi and Zhang-
Akiyama, 2009). 100 ng/ml ethidium bromide was added to the medium for
6–0 days. qPCR evaluation of mtDNA content by qPCR, transfection with Pol-
y(I:C)(HMW)/LyoVec (InvivoGen), and expression profiling are described in
Extended Experimental Procedures.
Immunoprecipitation/PCR
Mcl1/ MEFs transduced with an expression plasmid (pMSCV-IRES-
Hygro) encoding Flag-tagged mouse cGAS were treated with ABT-737
and Q-VD-Oph or left untreated. Following crosslinking of DNA and associ-
ated proteins, immunoprecipitation was performed with anti-FLAG M2
(Sigma) or mouse-IgG (BD) and coprecipitated DNA examined by real-
time qPCR. Oligonucleotide sequences are listed in Extended Experimental
Procedures.1560 Cell 159, 1549–1562, December 18, 2014 ª2014 Elsevier Inc.Statistics
Data and statistical methods are expressed as outlined in figure legends. Stan-
dard statistical methods were performed using Prism software (GraphPad).
Bonferroni post hoc test was used to correct for multiple testing.
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sets reported in this paper are GSE57934 and GSE59972.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and two tables and can be foundwith this article online at http://dx.doi.
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